TD Cowen analyst Phil Nadeau has maintained their bullish stance on VIR stock, giving a Buy rating on February 12.
Phil Nadeau has given his Buy rating due to a combination of factors that highlight Vir Biotechnology’s promising future. The company has a substantial cash reserve of $1.1 billion as of the end of 2024, which is expected to support its operations and key development programs until mid-2027. This financial stability allows Vir to focus on its top priority initiatives, including the pivotal ECLIPSE program for the tobe + eleb combination in chronic HDV, which is set to begin in the first half of 2025.
The ECLIPSE program is considered de-risked due to strong efficacy and safety data from earlier trials, positioning it as a potential new standard of care in HDV treatment. Additionally, Vir’s T-cell engager programs, VIR-5500 and VIR-5818, have shown promising anti-tumor activity and favorable safety profiles in early trials, reinforcing the potential of Vir’s platform to develop innovative cancer therapies. These factors collectively contribute to Nadeau’s confidence in Vir’s growth prospects and justify the Buy rating.
In another report released on February 12, Morgan Stanley also maintained a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VIR in relation to earlier this year.